In April 2022, Telix secured the exclusive worldwide rights to develop and commercialise radiolabelled forms of olaratumab for the diagnosis and treatment ...
The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support a U.S. Food and Drug Administration (F...
The FDA has also recently granted an orphan drug designation (ODD) to GIVI-MPC. Current treatments for DMD have limited therapeutic potential as unfortunat...
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the init...
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medic...
"Completion of enrollment in the first cohort of the Phase 1b MAD study is an important milestone in the development of this novel treatment for ADPKD," sa...
OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in...
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists...
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) fo...
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced that the U.S. Food and Drug Admini...
Conventional high-content screening experiments typically focus on extracting imaging data relating to predefined, specific features to identify drugs or d...
The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the ...
© 2025 Biopharma Boardroom. All Rights Reserved.
